All News
No Great Options for Treating VEXAS
d
MedPage Today
For patients with the auto-inflammatory disease VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.
Read Article
The Window of Opportunity (5.24.2024)
Dr. Jack Cush reviews the journal reports and news from the past week on RheumNow.com. This week: blockbuster drugs, opioids in rheumatology and nontreatment of inflammatory arthritis?
Read Article
Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohort
https://t.co/IB0cOAFnwl https://t.co/zpwm3JRKU4
Links:
Nelly ZIADE 🍀 Nellziade ( View Tweet)
The ability to predict hip fractures just went to a new level
https://t.co/k9cAPIJigd
A proteomic risk score was found to be strongly predictive of incident hip fractures in multiple independent populations
@NatureAging https://t.co/WZemPZqsev
Links:
Eric Topol EricTopol ( View Tweet)
Available online, open access:
A review of CAR-T call therapy in rheumatic disease by @RyuOhno06
See below diagram of CAR-T therapy mechanism in cancer.
https://t.co/WALWulEDkW https://t.co/k1FD0zHtWu
Links:
Seminars in Arthritis and Rheumatism seminarthrheum ( View Tweet)
Congratulations to CRA member Dr. Andrew Chow, recipient of the Ontario Rheumatology Association's Rheumatologist of the Year Award! 🏆👏 https://t.co/2fB77VOBhv
CRA SCR CRASCRRheum ( View Tweet)
Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development https://t.co/DFdQy1Rn3D
Peter Nash drpnash ( View Tweet)
Congratulations to CRA member Dr. Lauren King, recipient of the Ontario Rheumatology Association's Early Career Rheumatology Award! 🏆👏 https://t.co/iM5MxzVaTg
CRA SCR CRASCRRheum ( View Tweet)
Biomarkers Predictive of a Deucravacitinib Response in PsA
A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in PsA suggests specific biologic effects identified by biomarkers may predict clinical responses.
https://t.co/zsZl7JQydn https://t.co/4mGBYB4qU4
Dr. John Cush RheumNow ( View Tweet)
Lupus Research Alliance Grants for Lupus Innovation
The LRA) is proud to announce that nine international researchers are the recipients of this year’s Lupus Innovation Award (LIA).
https://t.co/v3S8u8aVvr https://t.co/Ve7OcIJT03
Dr. John Cush RheumNow ( View Tweet)
Save the date! We are covering #EULAR24 ! Will we see you there? https://t.co/aMGYnPxlXh
Dr. John Cush RheumNow ( View Tweet)
No Link Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined Significance
Annals of Internal Medicine reports a study of more than 75,000 persons screened for MGUS and found no association between AIRD and MGUS.
https://t.co/F8diWbUYPf https://t.co/M53Dgphcge
Dr. John Cush RheumNow ( View Tweet)
Australian multicenter KARAOKE RCT of 262 adults w/ Knee OA (w/ MRI effusion/synovitis) Rx w/ placebo vs , 2 g/d of krill oil showed no significant benefit in pain VAS score, −19.9 [krill oil] vs −20.2 [placebo]. https://t.co/aeNcVM0p8J https://t.co/2PR0PG6eWj
Dr. John Cush RheumNow ( View Tweet)
Upside/Downside of Steroids in Lupus Nephritis
A systematic review of randomized clinical trials of patients with biopsy-proven lupus nephritis (LN) demonstrates both the benefits and harms to early glucocorticoid (GC) regimens on lupus outcomes.
https://t.co/T88365IT9r https://t.co/xe5AmErLy2
Dr. John Cush RheumNow ( View Tweet)
384 Psoriasis pts followed mean 33 mos, 56 (14.6%) developed new-onset PsA. 311/384 (81%) had arthralgia (subclinical PsA) & 9.4% got PsA within 12 mos (23% by 36%). Subclinical more likely than PSO to get PsA (OR 11.7) https://t.co/9t41cjROwW https://t.co/9AelBwoRzs
Dr. John Cush RheumNow ( View Tweet)
Full read review of the benefits & impact of hydroxychloroquine in #SLE. Benefits on:
- T cells, cytokines, TLR signaling
- VTE prevention
- Decr CV risks
- Glucose & lipid benefits
- Pregnancy
https://t.co/bio9cYCIeb https://t.co/zfyUBaecbu
Dr. John Cush RheumNow ( View Tweet)
Brazilian Registry of Spondyloarthritis study of 1096 SpA pts, found 73% HLA-B27 positivity. B27+ signif assoc w/ males, earlier onset/Dx, uveitis, +FHx. B27 negativity assoc w/ psoriasis, higher peripheral arthritis/disease activity, worse QOL, mobility https://t.co/OUOVozdoXw https://t.co/z8hhPjRUfx
Dr. John Cush RheumNow ( View Tweet)
Small-molecule Drugs to Treat Systemic Lupus Erythematosus
A metanalysis of randomized controlled trials (RCTs) on treatments of systemic lupus erythematosus (SLE), confirm the efficacy of several targeted small-molecule drugs.
https://t.co/LKLUT8kLSk https://t.co/1SbUbiCpYs
Dr. John Cush RheumNow ( View Tweet)
Window of Opportunity in Psoriatic Arthritis
The Dutch southwest Early psoriatic arthritis (PsA) cohort study has demonstrated that the earlier the referral and diagnosis of PsA, the better the outcome.
https://t.co/eUL1wzrXVt https://t.co/XSETW2zpGs
Dr. John Cush RheumNow ( View Tweet)
Research presented at DDW 2024 demonstrated the superiority of guselkumab over ustekinumab or placebo in 1,021 patients with moderately to severely active Crohn's disease enrolled in the phase III GALAXI 2 and GALAXI 3 trials https://t.co/HdZf24Twsq https://t.co/REeAAskpX5
Dr. John Cush RheumNow ( View Tweet)